ATTR Cardiac Amyloidosis: Use the Diagnostic Gate

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Therapeutic approvals and trial results evolve. Verify the actual article, studied population, and current indication before teaching a treatment as established.

Can the nonbiopsy ATTR pathway be applied?. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Can the nonbiopsy ATTR pathway be applied?. Complete monoclonal screen — Serum and urine immunofixation plus free light chains; Cardiac tracer scan in context — Apply the established pathway only when its conditions fit; Discordant or monoclonal findings — Tissue confirmation and typing may be required. A positive cardiac scan cannot be interpreted in isolation from monoclonal testing. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

A protein-folding disease

Transthyretin deposition can produce a restrictive cardiomyopathy and extracardiac clues. Wild-type and hereditary disease require different family and genetic considerations.

Look beyond ejection fraction

Wall thickening, diastolic dysfunction, conduction disease, neuropathy, and carpal tunnel history can raise suspicion. Preserved ejection fraction does not imply a normal heart.

Apply the nonbiopsy gate

In the appropriate cardiac phenotype, grade 2–3 myocardial uptake on bone-tracer scintigraphy supports a nonbiopsy ATTR diagnosis only after AL has been excluded with serum free light chains and serum/urine immunofixation. Confirm myocardial uptake, rather than relying on blood-pool activity.

Handle a positive monoclonal screen

A monoclonal protein makes the scan alone insufficient to establish ATTR. Arrange specialist evaluation and tissue typing as indicated. Once ATTR is established, genetic testing distinguishes hereditary from wild-type disease and determines whether family counseling is needed.

Individualize management

Coordinate specialist assessment for disease-specific therapy and cautious congestion management. Autonomic dysfunction and fixed stroke volume can limit tolerance of routine cardiac drugs.

Keep evidence current

Therapeutic approvals and trial results evolve. Verify the actual article, studied population, and current indication before teaching a treatment as established.

Supporting evidence

Continue learning